In a phase Ib dose-escalation study (NCT02795988), HER-Vaxx was shown to be safe and prolong progression-free survival in patients with Her2-overexpressing gastro-esophageal junction (GEJ) and gastric cancer (GC) [10]. The gene discussed is ERBB2; the disease is gastric cancer.